AsclepiX Therapeutics: Funding, Investors & Team (Sep 2026)
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to design long-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body. AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases.
AsclepiX Therapeutics has raised $35.0M across 1 funding round on record, the most recent an undisclosed round of $35.0M announced in Jun 2020.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
AsclepiX Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2020.
AsclepiX Therapeutics Funding Rounds
AsclepiX Therapeutics Founders and Leadership Team
Contact details for the AsclepiX Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →AsclepiX Therapeutics Funding Compared to Other Biotechnology Startups
AsclepiX Therapeutics' latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like AsclepiX Therapeutics in Biotechnology and Baltimore
Companies Similar to AsclepiX Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
AsclepiX Therapeutics Funding FAQs
What does AsclepiX Therapeutics do?
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to design long-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body. AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases.
How much funding has AsclepiX Therapeutics raised?
AsclepiX Therapeutics has raised $35.0M across 1 round on record. The most recent is an undisclosed round of $35.0M announced in Jun 2020.
When did AsclepiX Therapeutics last raise funding?
AsclepiX Therapeutics' most recent funding round on record is an undisclosed round of $35.0M, announced in Jun 2020.
Who is the CEO of AsclepiX Therapeutics?
Wendy Perrow is listed as CEO at AsclepiX Therapeutics.
Where is AsclepiX Therapeutics headquartered?
AsclepiX Therapeutics is based in Baltimore, Maryland, United States.
How many employees does AsclepiX Therapeutics have?
AsclepiX Therapeutics is in the 11-50 employee band.
How does AsclepiX Therapeutics' funding compare to other Biotechnology startups?
AsclepiX Therapeutics' latest round of $35.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's AsclepiX Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for AsclepiX Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.